Nurix Therapeutics Q3 EPS $(0.68) Up From $(0.90) YoY, Sales $18.47M Beat $17.23M Estimate
Portfolio Pulse from Benzinga Newsdesk
Nurix Therapeutics reported Q3 losses of $(0.68) per share, a 24.44% increase YoY. The company's quarterly sales were $18.47M, beating the analyst consensus estimate of $17.23M by 7.18% and marking a 71.13% increase YoY.
October 12, 2023 | 8:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nurix Therapeutics reported improved Q3 earnings with reduced losses and increased sales YoY.
Nurix Therapeutics reported a decrease in losses and an increase in sales YoY, which indicates improved financial performance. This could potentially lead to a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100